126 related articles for article (PubMed ID: 30631034)
1. Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer.
Bonan NF; Kowalski D; Kudlac K; Flaherty K; Gwilliam JC; Falkenberg LG; Maradiaga E; DeCicco-Skinner KL
Oncogenesis; 2019 Jan; 8(1):1. PubMed ID: 30631034
[TBL] [Abstract][Full Text] [Related]
2. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract][Full Text] [Related]
3. MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.
Cataisson C; Michalowski AM; Shibuya K; Ryscavage A; Klosterman M; Wright L; Dubois W; Liu F; Zhuang A; Rodrigues KB; Hoover S; Dwyer J; Simpson MR; Merlino G; Yuspa SH
Sci Signal; 2016 Jun; 9(433):ra62. PubMed ID: 27330189
[TBL] [Abstract][Full Text] [Related]
4. Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis.
Decicco-Skinner KL; Jung SA; Tabib T; Gwilliam JC; Alexander H; Goodheart SE; Merchant AS; Shan M; Garber C; Wiest JS
Carcinogenesis; 2013 Dec; 34(12):2789-98. PubMed ID: 24067898
[TBL] [Abstract][Full Text] [Related]
5. Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice.
DeCicco-Skinner KL; Nolan SJ; Deshpande MM; Trovato EL; Dempsey TA; Wiest JS
PLoS One; 2013; 8(2):e56212. PubMed ID: 23457529
[TBL] [Abstract][Full Text] [Related]
6. Deletion of tumor progression locus 2 attenuates alcohol-induced hepatic inflammation.
Stice CP; Hussain S; Liu C; Ausman LM; Wang XD; Greenberg AS
Hepatobiliary Surg Nutr; 2016 Feb; 5(1):29-37. PubMed ID: 26904554
[TBL] [Abstract][Full Text] [Related]
7. Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice.
Gong J; Fang C; Zhang P; Wang PX; Qiu Y; Shen LJ; Zhang L; Zhu XY; Tian S; Li F; Wang Z; Huang Z; Wang A; Zhang XD; She ZG
Hepatology; 2019 Feb; 69(2):524-544. PubMed ID: 29381809
[TBL] [Abstract][Full Text] [Related]
8. Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer.
Lee HW; Choi HY; Joo KM; Nam DH
Int J Mol Sci; 2015 Feb; 16(3):4471-91. PubMed ID: 25723737
[TBL] [Abstract][Full Text] [Related]
9. Serine/threonine kinase, Cot/Tpl2, regulates renal cell apoptosis in ischaemia/reperfusion injury.
Yaomura T; Tsuboi N; Urahama Y; Hobo A; Sugimoto K; Miyoshi J; Matsuguchi T; Reiji K; Matsuo S; Yuzawa Y
Nephrology (Carlton); 2008 Oct; 13(5):397-404. PubMed ID: 18518937
[TBL] [Abstract][Full Text] [Related]
10. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
11. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation.
Senger K; Pham VC; Varfolomeev E; Hackney JA; Corzo CA; Collier J; Lau VWC; Huang Z; Hamidzhadeh K; Caplazi P; Peng I; Setiadi AF; Francis R; Paler-Martinez A; Kwon YC; Ramirez-Carrozzi V; Sun Y; Grigg PW; Roose-Girma M; Jeet S; Barck KH; Pham A; Ota N; Ha C; Stinson J; Guillory J; Tam L; Modrusan Z; Emson C; McKenzie BS; Townsend MJ; Carano RAD; Warming S; Vucic D; DeVoss J; Lee WP; Lill JR; Zarrin AA
Sci Signal; 2017 Apr; 10(475):. PubMed ID: 28420753
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
[TBL] [Abstract][Full Text] [Related]
13. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras.
Dlugosz AA; Hansen L; Cheng C; Alexander N; Denning MF; Threadgill DW; Magnuson T; Coffey RJ; Yuspa SH
Cancer Res; 1997 Aug; 57(15):3180-8. PubMed ID: 9242447
[TBL] [Abstract][Full Text] [Related]
14. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.
Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST
Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720
[TBL] [Abstract][Full Text] [Related]
15. TPL2 Is an Oncogenic Driver in Keratocanthoma and Squamous Cell Carcinoma.
Lee JH; Lee JH; Lee SH; Do SI; Cho SD; Forslund O; Inn KS; Lee JS; Deng FM; Melamed J; Jung JU; Jeong JH
Cancer Res; 2016 Nov; 76(22):6712-6722. PubMed ID: 27503930
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
17. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
18. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
[TBL] [Abstract][Full Text] [Related]
19. Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.
Li X; Liu C; Ip BC; Hu KQ; Smith DE; Greenberg AS; Wang XD
J Exp Clin Cancer Res; 2015 Nov; 34():138. PubMed ID: 26560698
[TBL] [Abstract][Full Text] [Related]
20. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
